Ratings by Wells Fargo (Tiago Fauth)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/13/2025 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 8/13/2025 | Liquidia Technologies | LQDA | Maintain | Overweight (N/A) |
|
Details | ||
| 8/8/2025 | Teck Resources Ltd | TECK | Maintain | Overweight (N/A) |
|
Details | ||
| 8/1/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 7/31/2025 | WAVE Life Sciences | WVE | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/31/2025 | United Therapeutics Corp. | UTHR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 7/22/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/10/2025 | Ultragenyx Pharma | RARE | Maintain | Overweight (N/A) |
|
Details | ||
| 7/10/2025 | Verona Pharma | VRNA | Downgrade | Equal Weight (Overweight) |
86.86 (106.91) |
23.08% | Details | |
| 6/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 6/30/2025 | Alnylam Pharmaceuticals | ALNY | Maintain | Equal Weight (N/A) |
|
Details | ||
| 6/20/2025 | Verona Pharma | VRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2025 | Liquidia Technologies | LQDA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/11/2025 | Insmed | INSM | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/28/2025 | Liquidia Technologies | LQDA | Maintain | Overweight (N/A) |
|
Details | ||
| 5/19/2025 | Inozyme Pharma Inc. | INZY | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 5/16/2025 | Inozyme Pharma Inc. | INZY | Downgrade | Equal Weight (Overweight) |
1.42 (4.00) |
181.69% | Details | |
| 4/30/2025 | Verona Pharma | VRNA | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2025 | United Therapeutics Corp. | UTHR | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 4/25/2025 | United Therapeutics Corp. | UTHR | Downgrade | Equal Weight (Overweight) |
296.42 (545.40) |
84% | Details | |
| 3/21/2025 | Tectonic Therapeutics Inc. | TECX | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/4/2025 | Pliant Therapeutics | PLRX | Maintain | Equal Weight (Equal Weight) |
|
Details | ||
| 2/19/2025 | Insmed | INSM | Maintain | (Overweight) |
|
Details | ||
| 2/10/2025 | Pliant Therapeutics | PLRX | Downgrade | Equal Weight (Overweight) |
11.95 (1.14) |
-90.46% | Details | |
| 1/31/2025 | Tectonic Therapeutics Inc. | TECX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/8/2025 | Verona Pharma | VRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 11/12/2024 | Tectonic Therapeutics Inc. | TECX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Disc Medicine | IRON | Maintain | Overweight (N/A) |
|
Details | ||
| 11/5/2024 | Verona Pharma | VRNA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/31/2024 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 10/17/2024 | WAVE Life Sciences | WVE | Maintain | Overweight (N/A) |
|
Details | ||
| 10/3/2024 | Verona Pharma | VRNA | New Coverage | Overweight (N/A) |
28.71 (86.86) |
202.54% | Details | |
| 8/22/2024 | Tectonic Therapeutics Inc. | TECX | New Coverage | Overweight (N/A) |
16.25 (29.34) |
80.55% | Details | |
| 8/22/2024 | BrightView Holdings | BV | New Coverage | Equal Weight (N/A) |
15.72 (12.65) |
-19.53% | Details | |
| 8/22/2024 | Disc Medicine | IRON | New Coverage | Overweight (N/A) |
49.31 (68.08) |
38.07% | Details | |
| 8/20/2024 | United Therapeutics Corp. | UTHR | Maintain | Overweight (N/A) |
|
Details | ||
| 6/18/2024 | Aerovate Therapeutics Inc | AVTE | Downgrade | Equal Weight (Overweight) |
1.65 (2.68) |
62.42% | Details | |
| 6/5/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 5/29/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details | ||
| 5/15/2024 | WAVE Life Sciences | WVE | New Coverage | Overweight (N/A) |
5.84 (5.81) |
-0.51% | Details | |
| 4/1/2024 | Aerovate Therapeutics Inc | AVTE | Maintain | Overweight (N/A) |
|
Details | ||
| 4/1/2024 | Insmed | INSM | Maintain | Overweight (N/A) |
|
Details |
